PMID- 29658117
OWN - NLM
STAT- MEDLINE
DCOM- 20190529
LR  - 20211204
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Print)
IS  - 0019-2805 (Linking)
VI  - 154
IP  - 3
DP  - 2018 Jul
TI  - Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
PG  - 331-345
LID - 10.1111/imm.12936 [doi]
AB  - The entirety of human leukocyte antigen (HLA)-presented peptides is referred to 
      as the HLA ligandome of a cell or tissue, in tumours often termed 
      immunopeptidome. Mapping the tumour immunopeptidome by mass spectrometry (MS) 
      comprehensively views the pathophysiologically relevant antigenic signature of 
      human malignancies. MS is an unbiased approach stringently filtering the 
      candidates to be tested as opposed to epitope prediction algorithms. In the 
      setting of peptide-specific immunotherapies, MS-based strategies significantly 
      diminish the risk of lacking clinical benefit, as they yield highly enriched 
      amounts of truly presented peptides. Early immunopeptidomic efforts were severely 
      limited by technical sensitivity and manual spectra interpretation. The 
      technological progress with development of orbitrap mass analysers and enhanced 
      chromatographic performance led to vast improvements in mass accuracy, 
      sensitivity, resolution, and speed. Concomitantly, bioinformatic tools were 
      developed to process MS data, integrate sequencing results, and deconvolute 
      multi-allelic datasets. This enabled the immense advancement of tumour 
      immunopeptidomics. Studying the HLA-presented peptide repertoire bears high 
      potential for both answering basic scientific questions and translational 
      application. Mapping the tumour HLA ligandome has started to significantly 
      contribute to target identification for the design of peptide-specific cancer 
      immunotherapies in clinical trials and compassionate need treatments. In contrast 
      to prediction algorithms, rare HLA allotypes and HLA class II can be adequately 
      addressed when choosing MS-guided target identification platforms. Herein, we 
      review the identification of tumour HLA ligands focusing on sources, methods, 
      bioinformatic data analysis, translational application, and provide an outlook on 
      future developments.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Freudenmann, Lena Katharina
AU  - Freudenmann LK
AUID- ORCID: 0000-0002-9827-4979
AD  - Interfaculty Institute for Cell Biology, Department of Immunology, University of 
      Tubingen, Tubingen, Germany.
AD  - DKFZ Partner Site Tubingen, German Cancer Consortium (DKTK), Tubingen, Germany.
FAU - Marcu, Ana
AU  - Marcu A
AUID- ORCID: 0000-0003-0808-8097
AD  - Interfaculty Institute for Cell Biology, Department of Immunology, University of 
      Tubingen, Tubingen, Germany.
FAU - Stevanovic, Stefan
AU  - Stevanovic S
AUID- ORCID: 0000-0003-1954-7762
AD  - Interfaculty Institute for Cell Biology, Department of Immunology, University of 
      Tubingen, Tubingen, Germany.
AD  - DKFZ Partner Site Tubingen, German Cancer Consortium (DKTK), Tubingen, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180508
PL  - England
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Peptides)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/chemistry/immunology/metabolism
MH  - Computational Biology/methods
MH  - *Epitope Mapping/methods
MH  - Epitopes/*immunology/isolation & purification/metabolism
MH  - HLA Antigens/*immunology/metabolism
MH  - Humans
MH  - Immunotherapy
MH  - *Ligands
MH  - *Mass Spectrometry/methods
MH  - Neoplasms/*immunology/metabolism/therapy
MH  - Peptides/chemistry/immunology/metabolism
MH  - Precision Medicine/methods
MH  - Protein Processing, Post-Translational
MH  - Translational Research, Biomedical
PMC - PMC6002237
OTO - NOTNLM
OT  - HLA ligand
OT  - TAA
OT  - cancer immunotherapy
OT  - immunopeptidome
OT  - mass spectrometry
OT  - tumour-associated antigen
EDAT- 2018/04/17 06:00
MHDA- 2019/05/30 06:00
PMCR- 2019/07/01
CRDT- 2018/04/17 06:00
PHST- 2018/03/02 00:00 [received]
PHST- 2018/03/29 00:00 [revised]
PHST- 2018/04/02 00:00 [accepted]
PHST- 2018/04/17 06:00 [pubmed]
PHST- 2019/05/30 06:00 [medline]
PHST- 2018/04/17 06:00 [entrez]
PHST- 2019/07/01 00:00 [pmc-release]
AID - IMM12936 [pii]
AID - 10.1111/imm.12936 [doi]
PST - ppublish
SO  - Immunology. 2018 Jul;154(3):331-345. doi: 10.1111/imm.12936. Epub 2018 May 8.